Therma Bright Improves COVID-19 Rapid Saliva Antigen Test To 86% Sensitivity, 100% Specificity

Therma Bright Inc (TSXV: THRM) this afternoon halted its equity from trading for the dying minutes of the days session so as to release the latest results from its COVID-19 rapid saliva antigen test while announcing it is preparing for prospective studies. The latest results from testing on the device returned a test sensitivity of 86%, along with a specificity of 100% for the CoviSafe rapid antigen test.

The results released this evening following preliminary results released in early December during a feasibility study. At the time, test sensitivity was reported as being 80%, while specificity was reported at 90%, making the latest figures a slight improvement.

The company also noted that this sensitivity was based on samples with an RT_PCR Ct value below 30, while sensitivity with values of 25 or lower was 100%. Ct is based on the number of times that a DNA or RNA sample needs to be amplified in order for it to be detected. As a result, the lower the Ct value, the higher the amount of viral RNA present in the sample. The minimum standard for home-use approval with Health Canada and the US FDA is 80% sensitivity.

The company is also reportedly in discussions with sites in Ontario, the US and internationally to conduct prospective studies with the test. Initial testing will be for both symptomatic and asymptomatic patients, with testing to begin upon approval from one of the locations. The company is currently looking to test a minimum of 100 prototype devices using saliva from participants to further improve the device. The final version will then be used on a minimum of 300 patients to collect the required data for regulatory approval with Health Canada, the FDA, the EUA, and to receive the CE mark from Europe.

Therma Bright Inc last traded at $0.87 on the TSX Venture.


Information for this briefing was found via Sedar and Therma Bright Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered...

Monday, May 3, 2021, 09:24:15 AM

YouTube Updates Misinformation Policies, Will Remove Content on Covid-19 Myths, Alternative Cancer Treatments

Earlier this week, YouTube unveiled a refined policy aimed at curbing medical misinformation on its...

Saturday, August 19, 2023, 07:18:00 AM

China Protestors Have Zero Tolerance For China’s Zero COVID Policy

Beijing attempts to walk back on its stringent pandemic measures as uprising has been gaining...

Tuesday, November 29, 2022, 10:23:00 AM

Global Economy Forecast to Contract by 5.6% in 2020 Due to Pandemic

The coronavirus pandemic has plunged the global economy into the worst recession in over 80...

Tuesday, December 15, 2020, 11:57:00 AM

Pentagon’s Secret Anti-Vax Campaign to Undermine China During Pandemic Exposed

An extensive investigation by Reuters has unveiled a clandestine campaign by the U.S. military aimed...

Sunday, June 16, 2024, 11:45:00 AM